Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from thePharmaLetter

03:24 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "thePharmaLetter" found in our extensive news archives from over 250 global news sources.

More Information about thePharmaLetter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about thePharmaLetter for you to read. Along with our medical data and news we also list thePharmaLetter Clinical Trials, which are updated daily. BioPortfolio also has a large database of thePharmaLetter Companies for you to search.

Showing News Articles 1–25 of 2,400+ from thePharmaLetter

Sunday 18th February 2018

Look back at pharma news in week to Feb 16

In the regulatory news sector last week, Vertex Pharmaceuticals came up with another drug approval, this…

Friday 16th February 2018

Platform’s potential for early-stage detection cannot be ignored, says Owlstone Medical CEO

Sometimes a device or diagnostic comes along that even the most drug-centric of pharma companies cannot…

BRIEF — Pair of allergy treatments made available for Japanese children

Both ALK-Abelló and Stallergenes Greer were able to announce Japanese approval of pediatric use for…

Celularity attracts big bucks and names with vision for longer life

In biotech, investors are used to hearing big pledges from start-ups about their capacity to meet needs…

Russian government plans on innovative drugs and centralized mechanism for their purchase

The Russian Federal Anti-Monopoly Service (FAS) has announced its plans to submit a proposal to the national…

Trial tinkering seen as bad sign for Biogen's aducanumab

A day after Merck & Co pulled the plug on its Phase III verubecestat program, alarm bells started ringing…

Roche buys full control of health tech start-up Flatiron for $1.9 billion

Roche has signed a definitive agreement under which it will acquire all shares of Flatiron Health, following…

New production facility for APIs to be built in Russia

Active component, one of the largest producers of active pharmaceutical ingredients (APIs) in Russia,…

BRIEF—More drug price gouging revealed

Another instance of massive price gouging in the US pharma market has been revealed by the Financial…

FDA pilots cross-functional teams to expedite product review process

Recognizing an “urgent need for new medical treatments” for many neurological disorders, the FDA…

BRIEF—Sumitomo Dainippon drops NASH candidate in Japan and South Korea

Japan’s Sumitomo Dainippon has handed back to Intercept Pharmaceuticals the rights to develop and commercialize…

Another disappointment with Bavencio, this time in lung cancer trial

In another setback for their immuno-oncology drug, Germany’s Merck and Pfizer announced disappointing…

Brexit: Uncertainty and ambiguity for pharma sector

It has been nearly two years since the UK voted to leave the European Union. While we find ourselves…

On eve of acquisition, Sanofi and Ablynx expand licensing deal

Sanofi and its soon-to-be subsidiary Ablynx have expanded a licensing deal to include two additional…

B-MS and Nektar anti-cancer deal lays out new path for combination therapy, says report

On February 14, Nektar Therapeutics and Bristol-Myers Squibb announced a record-breaking partnership…

Thursday 15th February 2018

Investors envisage further Ipsen growth after latest results

French drugmaker Ipsen followed up its outstanding 2017 financial results – that included a 21% rise…

Luke warm ICER backing on cost-effectiveness of new eye drug Luxturna

The USA-based Institute for Clinical and Economic Review (ICER) on Wednesday released a Final Evidence…

Nexavar included in NICE’s thyroid cancer recommendations

Nexavar (sorafenib) is by no means Bayer’s newest cancer drug but there is life in the blockbuster…

Oxford BioMedica set to earn $100 million in deal with Sanofi takeover target

UK gene cell therapy designer Oxford BioMedica’s shares jumped as much as 11.2% to 12.30 pence this…

ABAC Therapeutics raises 16 million euros from investors including Debiopharm

Spain-based ABAC Therapeutics, a leader in pathogen-specific antibiotics, announced today the closing…

Health Canada warns on Tecentriq myocarditis risk

Oncologists in Canada have been warned by the government about risks associated with using Tecentriq…

NICE recommends Ipsen drug for medullary thyroid cancer

Ipsen’s good day has got even better with news that the National Institute for Health and Care Excellence…

Ferring investing 30 million francs in new biotech center

Privately-held Swiss drugmaker Ferring Pharmaceuticals announced today that it is expanding its capabilities…

BRIEF—bluebird bio names Alison Finger as CCO

US biotech bluebird bio, a clinical-stage company committed to developing potentially transformative…

Santhera snaps up CF drug in all-Swiss deal

Santhera Pharmaceuticals has signed a deal to give it exclusive worldwide rights to a drug developed…


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks